Premium
Intravenous immunoglobulin and suppression of the production of matrix metalloproteinase‐9
Author(s) -
Matsuo Hidenori
Publication year - 2015
Publication title -
clinical and experimental neuroimmunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.297
H-Index - 15
ISSN - 1759-1961
DOI - 10.1111/cen3.12223
Subject(s) - multiple sclerosis , matrix metalloproteinase , matrix metalloproteinase 9 , antibody , metalloproteinase , tissue inhibitor of metalloproteinase , in vitro , matrix (chemical analysis) , medicine , immunology , immunoglobulin g , matrix metalloproteinase 3 , chemistry , biochemistry , chromatography
Matrix metalloproteinase‐9 is a biomarker and therapeutic target in multiple sclerosis. Okada and Adachi reported the matrix metalloproteinase‐9/tissue inhibitor of metalloproteinase‐1 imbalance was a predisposition in patients with multiple sclerosis, and human immunoglobulin G restored it in vitro , supporting the potential of intravenous immunoglobulin therapy in multiple sclerosis.